Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2021 – Lung Cancer
ASCO 2021 – Lung Cancer
Clinical Utility of Cell-Free Genomic Profiling in Advanced Lung Adenocarcinoma
ASCO 2021 – Lung Cancer
Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma.
Read More ›
CodeBreaK 100: Efficacy Results from a Phase 2 Trial in Pretreated KRAS G12C–Mutated NSCLC
ASCO 2021 – Lung Cancer
Sotorasib, an oral
KRAS
inhibitor, was effective across specified subgroups of patients with
KRAS
G12C–mutated non–small-cell lung cancer (NSCLC).
Read More ›
Cost Evaluation of Adjunctive Osimertinib Use in Resected EGFR-Positive NSCLC
ASCO 2021 – Lung Cancer
The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected
EGFR
-positive non–small-cell lung cancer (NSCLC).
Read More ›
Active Multimodal Intervention Reduced Racial Disparities in Delivery of Timely Lung Cancer Surgery
ASCO 2021 – Lung Cancer
The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer.
Read More ›
EGFR and MET Combined Inhibition in EGFR-Mutated Advanced NSCLC: A Real-World Study
ASCO 2021 – Lung Cancer
The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed
MET
amplification after prior EGFR-TKI therapy in
EGFR
-mutated non–small-cell lung cancer (NSCLC).
Read More ›
CheckMate-9LA: Nivolumab + Ipilimumab in Advanced NSCLC – Two-Year Update
ASCO 2021 – Lung Cancer
First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up.
Read More ›
Racial Disparities in Lung Adenocarcinoma: The Contribution of African Ancestry
ASCO 2021 – Lung Cancer
Findings of a global ancestry analysis confirm that African ancestry is associated with worse survival outcomes among patients with lung adenocarcinoma.
Read More ›
Clinical Trial Enrollment and Biomarker Testing in NSCLC: Racial Disparities
ASCO 2021 – Lung Cancer
Comprehensive biomarker testing and clinical trial participation rates were significantly lower for black patients in the United States compared with white patients with advanced non–small-cell lung cancer (NSCLC).
Read More ›
CheckMate-227: Nivolumab plus Ipilimumab in Advanced NSCLC – Four-Year Update
ASCO 2021 – Lung Cancer
Nivolumab in combination with ipilimumab delivers durable, long-term survival benefit versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression with 4 years of follow-up.
Read More ›
GEOMETRY Mono-1: Capmatinib in MET Exon 14–Mutated Advanced NSCLC
ASCO 2021 – Lung Cancer
Deep and durable responses with a manageable toxicity profile were achieved with capmatinib treatment in patients with
MET
exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us